Cargando…

Protective effects of glucagon‐like peptide‐1 on cardiac remodeling by inhibiting oxidative stress through mammalian target of rapamycin complex 1/p70 ribosomal protein S6 kinase pathway in diabetes mellitus

AIMS/INTRODUCTION: Although increased reactive oxygen species (ROS) generation is a major mechanism leading to cardiac remodeling in diabetes mellitus, research into the effects of anti‐oxidation on diabetic cardiac remodeling remains scarce and controversial. Glucagon‐like peptide‐1 (GLP‐1) shows p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Dongjuan, Jiang, Longfu, Feng, Beili, He, Nana, Zhang, Yue, Ye, Honghua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6944832/ https://www.ncbi.nlm.nih.gov/pubmed/31199578 http://dx.doi.org/10.1111/jdi.13098

Ejemplares similares

The Effects of Glucagon-like Peptide-2 on the Tight Junction and Barrier Function in IPEC-J2 Cells through Phosphatidylinositol 3-kinase–Protein Kinase B–Mammalian Target of Rapamycin Signaling Pathway
por: Yu, Changsong, et al.
Publicado: (2016)

Impairing the production of ribosomal RNA activates mammalian target of rapamycin complex 1 signalling and downstream translation factors
por: Liu, Rui, et al.
Publicado: (2014)

Increasing Fracture Risk Associates With Plasma Circulating MicroRNAs in Aging People’s Sarcopenia
por: He, Nana, et al.
Publicado: (2021)

SIRT1 Negatively Regulates the Mammalian Target of Rapamycin
por: Ghosh, Hiyaa Singhee, et al.
Publicado: (2010)

Dysregulation of the Mammalian Target of Rapamycin and p27(Kip1) Promotes Intimal Hyperplasia in Diabetes Mellitus
por: Woods, Thomas Cooper
Publicado: (2013)

Computational Peptide Design Cotargeting Glucagon and Glucagon-like Peptide-1 Receptors
por: Vishnoi, Shubham, et al.
Publicado: (2023)

Antagonising Chromatin Remodelling Activities in the Regulation of Mammalian Ribosomal Transcription
por: Tariq, Kanwal, et al.
Publicado: (2021)

Transforming somatic mutations of mammalian target of rapamycin kinase in human cancer
por: Yamaguchi, Hiroyuki, et al.
Publicado: (2015)

Coagonist of glucagon-like peptide-1 and glucagon receptors ameliorates kidney injury in murine models of obesity and diabetes mellitus
por: Patel, Vishal J, et al.
Publicado: (2018)

Stability of glucagon-like peptide 1 and glucagon in human plasma
por: Wewer Albrechtsen, Nicolai J, et al.
Publicado: (2015)

Pharmacological Inhibition of ULK1 Kinase Blocks Mammalian Target of Rapamycin (mTOR)-dependent Autophagy
por: Petherick, Katy J., et al.
Publicado: (2015)

Involvement of Target of Rapamycin (TOR) Signaling in the Regulation of Crosstalk between Ribosomal Protein Small Subunit 6 Kinase-1 (RPS6K-1) and Ribosomal Proteins
por: Bakshi, Achala, et al.
Publicado: (2023)

The Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Stimulates Mechanistic Target of Rapamycin (mTOR) Signaling via PKA And Akt
por: Le, Thao D V, et al.
Publicado: (2021)

Klebsazolicin inhibits 70S ribosome by obstruction of the peptide exit tunnel
por: Metelev, Mikhail, et al.
Publicado: (2017)

Glucagon-like peptide 1 (GLP-1)
por: Müller, T.D., et al.
Publicado: (2019)

Glucagon-Like Peptide-1 and Diabetes
por: Monami, Matteo
Publicado: (2011)

Rapamycin inhibits spermatogenesis by changing the autophagy status through suppressing mechanistic target of rapamycin-p70S6 kinase in male rats
por: Liu, Shangjing, et al.
Publicado: (2017)

Crystal Structure of Glucagon-like Peptide-1 in Complex with the Extracellular Domain of the Glucagon-like Peptide-1 Receptor
por: Underwood, Christina Rye, et al.
Publicado: (2010)

Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
por: Lee, Seungah, et al.
Publicado: (2017)

Mechanistic Target of Rapamycin Complex 1/S6 Kinase 1 Signals Influence T Cell Activation Independently of Ribosomal Protein S6 Phosphorylation
por: Salmond, Robert J., et al.
Publicado: (2015)

Circulating MicroRNAs in Plasma Decrease in Response to Sarcopenia in the Elderly
por: He, Nana, et al.
Publicado: (2020)

Effects of glucagon-like peptide 1 receptor agonists on comorbidities in older patients with diabetes mellitus
por: Onoviran, Olusola F., et al.
Publicado: (2019)

Correlation between gut microbiota and glucagon-like peptide-1 in patients with gestational diabetes mellitus
por: Liang, Yun-Yi, et al.
Publicado: (2022)

Can phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibition ERase them all?
por: Meyer, Dominique S, et al.
Publicado: (2010)

The mammalian target of rapamycin (mTOR) kinase mediates haloperidol-induced cataleptic behavior
por: Ramírez-Jarquín, Uri Nimrod, et al.
Publicado: (2020)

Glucagon-like peptide-1 and glucagon-like peptide-2 regulation during human liver regeneration
por: Ammann, Markus, et al.
Publicado: (2023)

Glucagon-Like Peptide-1 Protects Against Atrial Fibrillation and Atrial Remodeling in Type 2 Diabetic Mice
por: Bohne, Loryn J., et al.
Publicado: (2023)

Glucagon-Like Peptide-1 Gene Therapy
por: Rowzee, Anne M., et al.
Publicado: (2011)

Glucagon-Like Peptide-1 and Diabetes 2012
por: Monami, Matteo, et al.
Publicado: (2012)

Glucagon-like peptide-1 analogues: An overview
por: Gupta, Vishal
Publicado: (2013)

Glucagon and Its Receptors in the Mammalian Heart
por: Neumann, Joachim, et al.
Publicado: (2023)

Glucagon-like peptide 1 and Glucagon-like peptide 2 in relation to osteoporosis in non-diabetic postmenopausal women
por: Montes Castillo, María Cristina, et al.
Publicado: (2019)

Regulation of intestinal lipid and lipoprotein metabolism by the proglucagon-derived peptides glucagon like peptide 1 and glucagon like peptide 2
por: Mulvihill, Erin E.
Publicado: (2018)

Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice
por: Pocai, Alessandro, et al.
Publicado: (2009)

Rapamycin inhibition of baculovirus recombinant (BVr) ribosomal protein S6 kinase (S6K1) is mediated by an event other than phosphorylation
por: Beigh, Mushtaq A, et al.
Publicado: (2012)

Design of Glucagon-Like Peptide-1 Receptor Agonist for Diabetes Mellitus from Traditional Chinese Medicine
por: Tang, Hsin-Chieh, et al.
Publicado: (2014)

Clinical Application of Glucagon-Like Peptide 1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus
por: Cho, Young Min, et al.
Publicado: (2013)

Interactive contribution of hyperinsulinemia, hyperglycemia, and mammalian target of rapamycin signaling to valvular interstitial cell differentiation and matrix remodeling
por: Selig, Jessica I., et al.
Publicado: (2022)

The Clinical Efficacy and Safety of Glucagon-Like Peptide-1 (GLP-1) Agonists in Adults with Type 2 Diabetes Mellitus
por: Brice, Kira R., et al.
Publicado: (2011)

The low level of glucagon-like peptide-1 (glp-1) is a risk factor of type 2 diabetes mellitus
por: Lastya, Agus, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ajv7jdocjc5o9dgga6lqd4id7f